Effect of serum high-sensitivity C-reactive protein and tumor necrosis factor-alpha on prognosis of patients undergoing percutaneous coronary intervention

J. Fu
{"title":"Effect of serum high-sensitivity C-reactive protein and tumor necrosis factor-alpha on prognosis of patients undergoing percutaneous coronary intervention","authors":"J. Fu","doi":"10.3760/CMA.J.ISSN.1008-6315.2020.01.009","DOIUrl":null,"url":null,"abstract":"Objective To investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-alpha (TNF-α) on the prognosis of patients undergoing percutaneous coronary intervention (PCI). Methods From January 2016 to December 2017, 197 patients with acute coronary syndrome (ACS) treated by PCI in our hospital were divided into MACE group (39 cases) and non-MACE group (158 cases) according to whether major adverse cardiovascular events (MACE) occurred after PCI.The serum levels of hs-CRP and TNF-α were compared between the two groups before and 48 hours after PCI.The risk factors of MACE after PCI were analyzed by logistic regression analysis. Results One year follow-up results after PCI showed that 39 of 197 ACS patients had MACE after PCI, with an incidence of 19.8% (39/197). There were 39 cases in MACE group and 158 cases in non-MACE group.The serum hs-CRP of the MACE group and the non-MACE group before PCI were (9.70±4.71), (7.50±4.61) mg/L respectively, and 48 hours after PCI were (15.37±5.01), (12.16±4.38) mg/L, respectively.There were significant differences between the two groups (all P<0.01). The serum TNF-α levels before PCI in MACE group and non-MACE group were (33.1±8.9), (25.7±8.0) ng/L, respectively, and 48 hours after PCI were (47.6±8.1), (32.4±7.6) ng/L, respectively.There were significant differences between the two groups (P<0.05 or P<0.01). The results of logistic regression analysis showed that preoperative serum hs CRP and TNF-α were the risk factors of mace in PCI patients (OR (95% CI) was 2.069 (1.715-3.358), 2.825 (1.614-4.372), P value was 0.020 and 0.027, respectively). Conclusion The serum levels of hs-CRP and TNF-α are related to the prognosis of patients with PCI.The serum levels of hs-CRP and TNF-α before PCI are risk factors for MACE, which can be used as independent predictors of MACE. Key words: Acute coronary syndrome; Percutaneous coronary intervention; Major adverse cardiovascular events; High-sensitivity C-reactive protein; Tumor necrosis factor-alpha","PeriodicalId":10365,"journal":{"name":"中国综合临床","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国综合临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6315.2020.01.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-alpha (TNF-α) on the prognosis of patients undergoing percutaneous coronary intervention (PCI). Methods From January 2016 to December 2017, 197 patients with acute coronary syndrome (ACS) treated by PCI in our hospital were divided into MACE group (39 cases) and non-MACE group (158 cases) according to whether major adverse cardiovascular events (MACE) occurred after PCI.The serum levels of hs-CRP and TNF-α were compared between the two groups before and 48 hours after PCI.The risk factors of MACE after PCI were analyzed by logistic regression analysis. Results One year follow-up results after PCI showed that 39 of 197 ACS patients had MACE after PCI, with an incidence of 19.8% (39/197). There were 39 cases in MACE group and 158 cases in non-MACE group.The serum hs-CRP of the MACE group and the non-MACE group before PCI were (9.70±4.71), (7.50±4.61) mg/L respectively, and 48 hours after PCI were (15.37±5.01), (12.16±4.38) mg/L, respectively.There were significant differences between the two groups (all P<0.01). The serum TNF-α levels before PCI in MACE group and non-MACE group were (33.1±8.9), (25.7±8.0) ng/L, respectively, and 48 hours after PCI were (47.6±8.1), (32.4±7.6) ng/L, respectively.There were significant differences between the two groups (P<0.05 or P<0.01). The results of logistic regression analysis showed that preoperative serum hs CRP and TNF-α were the risk factors of mace in PCI patients (OR (95% CI) was 2.069 (1.715-3.358), 2.825 (1.614-4.372), P value was 0.020 and 0.027, respectively). Conclusion The serum levels of hs-CRP and TNF-α are related to the prognosis of patients with PCI.The serum levels of hs-CRP and TNF-α before PCI are risk factors for MACE, which can be used as independent predictors of MACE. Key words: Acute coronary syndrome; Percutaneous coronary intervention; Major adverse cardiovascular events; High-sensitivity C-reactive protein; Tumor necrosis factor-alpha
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清高敏c反应蛋白和肿瘤坏死因子- α对经皮冠状动脉介入治疗患者预后的影响
目的探讨血清高敏c反应蛋白(hs-CRP)和肿瘤坏死因子-α (TNF-α)对经皮冠状动脉介入治疗(PCI)患者预后的影响。方法选取2016年1月~ 2017年12月我院行PCI治疗的急性冠脉综合征(ACS)患者197例,根据PCI术后是否发生重大不良心血管事件(MACE)分为MACE组(39例)和非MACE组(158例)。比较两组患者PCI治疗前及术后48 h血清hs-CRP、TNF-α水平。采用logistic回归分析PCI术后MACE发生的危险因素。结果197例ACS患者PCI术后1年随访结果显示,39例ACS患者PCI术后发生MACE,发生率为19.8%(39/197)。MACE组39例,非MACE组158例。PCI术前MACE组和非MACE组血清hs-CRP分别为(9.70±4.71)、(7.50±4.61)mg/L, PCI术后48 h hs-CRP分别为(15.37±5.01)、(12.16±4.38)mg/L。两组间比较差异均有统计学意义(P<0.01)。MACE组和非MACE组PCI术前血清TNF-α水平分别为(33.1±8.9)、(25.7±8.0)ng/L, PCI术后48 h血清TNF-α水平分别为(47.6±8.1)、(32.4±7.6)ng/L。两组间差异均有统计学意义(P<0.05或P<0.01)。logistic回归分析结果显示,术前血清hs CRP和TNF-α是PCI患者发生mace的危险因素(OR (95% CI)分别为2.069(1.715 ~ 3.358)、2.825 (1.614 ~ 4.372),P值分别为0.020和0.027)。结论血清hs-CRP、TNF-α水平与PCI患者预后有关。PCI术前血清hs-CRP、TNF-α水平是MACE的危险因素,可作为MACE的独立预测因子。关键词:急性冠脉综合征;经皮冠状动脉介入治疗;主要不良心血管事件;高敏c反应蛋白;肿瘤坏死因子
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
16855
期刊介绍: Clinical Medicine of China is an academic journal organized by the Chinese Medical Association (CMA), which mainly publishes original research papers, reviews and commentaries in the field. Clinical Medicine of China is a source journal of Peking University (2000 and 2004 editions), a core journal of Chinese science and technology, an academic journal of RCCSE China Core (Extended Edition), and has been published in Chemical Abstracts of the United States (CA), Abstracts Journal of Russia (AJ), Chinese Core Journals (Selection) Database, Chinese Science and Technology Materials Directory, Wanfang Database, China Academic Journal Database, JST Japan Science and Technology Agency Database (Japanese) (2018) and other databases.
期刊最新文献
Comparison of the efficacy of midcaudal combined approach and cephalic middle approach in laparoscopic complete mesocolic excision for right hemicolon cancer with incomplete ileus The clinical advantage of nano carbon suspension mapping in the number of axillary lymph nodes detected after neoadjuvant chemotherapy for breast cancer Correlation of serum monokine induced by IFN-γ and interleukin9 to HBV pre-C/BCP mutation and their influences on the response to interferon therapy in patients with HBeAg-positive chronic hepatitis B Study on the relationship between Plasma Pro amino terminal brain natriuretic peptide, left ventricular mass index and the prognosis in elderly heart failure patients with preserved ejection fraction Clinical analysis of 16 cases of remedial stent placement after mechanical thrombectomy for acute cerebral infarction
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1